Schering-Plough Plans Novel Oral Contraceptive Filing In 2009
This article was originally published in The Pink Sheet Daily
Executive Summary
Novel oral contraceptive, gained through the acquisition of Organon Biosciences, would be the first containing a natural estrogen.
You may also be interested in...
Schering-Plough Makes Its Move, Snapping Up Organon For $14.4 Billion
After much talk of a major acquisition, Schering buys the Organon pharmaceutical and animal health business of Akzo Nobel.
Teva Says The Time Is Right For Two Big Immunology Biosimilar Launches
US market access senior VP Tom Rainey talks to Scrip about the upcoming launches of biosimilar versions of Humira and Stelara.
Darzalex Surpasses Stelara As J&J’s Best-Selling Drug
Sales of Stelara are expected to begin tapering off later this year when the first biosimilars launch in mid-2024 in Europe and later in the US.